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Background: Despite a good prognosis for most melanoma survivors, many experience substantial fear of new or
recurrent melanoma, worry and anxiety about the future, and unmet healthcare needs. In this protocol, we outline
the design and methods of the Melanoma Care Study for melanoma survivors at high risk of developing new primary
disease. The objective of this study is to evaluate the efficacy and cost-effectiveness of a psycho-educational intervention
for improving psychological and behavioural adjustment to melanoma risk.
Design: The study design is a two-arm randomised controlled trial comparing a psycho-educational intervention to usual
care.
Methods: The intervention is comprised of a newly-developed psycho-educational booklet and three telephone sessions
delivered by a trained psychologist. A total of 154 melanoma survivors at high risk of developing new primary disease
who are attending one of three melanoma high risk clinics in New South Wales, Australia, will be recruited. Participants
will be assessed at baseline (6 weeks before their high risk clinic dermatological appointment), and then 4 weeks and
6 months after their appointment. If effectiveness of the intervention is demonstrated at 6 months, an additional
assessment at 12 months is planned. The primary outcome is fear of new or recurrent melanoma, as assessed by
the Fear of Cancer Recurrence Inventory (FCRI). Secondary outcomes include anxiety, depression, unmet supportive
care needs, satisfaction with clinical care, knowledge, behavioural adjustment to melanoma risk, quality of life, and
cost-effectiveness of the intervention from a health system perspective. Following the intention-to-treat principle,
linear mixed models will be used to analyse the data to account for repeated measures. A process evaluation will
also be carried out to inform and facilitate potential translation and implementation into clinical practice.
Discussion: This study will provide high quality evidence on the efficacy and cost-effectiveness of a psycho-educational
intervention aimed at improving psychological and behavioural adjustment amongst melanoma survivors at high risk of
new primary disease.
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InterventionBackground
Despite a strong awareness of skin cancer prevention
and early detection, Australia still has the highest inci-
dence of melanoma in the world. With more than
12,500 cases diagnosed annually in Australia, melanoma
is the fourth most common cancer (Australian Cancer
Incidence and Mortality (ACIM) 2010). Melanoma de-
tected at an early stage has a 5-year survival rate of
greater than 90 %; however, this decreases to around
50 % with diagnosis at a late stage (Balch et al. 2009). In
Australia, the burden of melanoma is considerable. It is
the eighth most common cause of death from cancer,
causing more than 1500 deaths per year and accounting
for 22,800 disability-adjusted life years (DALYs). Of
these, 17,200 are years lost due to premature death and
5600 are years of healthy life lost due to disease, disabil-
ity or injury (Australian Cancer Incidence and Mortality
(ACIM) 2010; Australian Institute of Health and Welfare
& Australasian Association of Cancer Registries 2012).
Once a melanoma has been detected, the risk of devel-
oping another melanoma is much higher. A person who
has had one previous melanoma has a 9-fold risk of
developing a new primary melanoma compared to the
average person in Australia, and the risk remains ele-
vated more than 20 years after the initial melanoma
diagnosis (Bradford et al. 2010). Risk of recurrence (i.e.
that the melanoma will spread to another part of the
body) is related to the clinical features of a person’s mela-
noma, and is estimated overall to be 9 % (Bradford et al.
2010).
A melanoma diagnosis is often perceived as life-threat-
ening and can trigger psychological distress, particularly
amongst those at higher risk of recurrence. Research in-
volving melanoma survivors has found that fear of new
or recurrent cancer (FCR) (Vickberg 2003) and anxiety
are common among this group (Kasparian et al. 2009;
McLoone et al. 2013a). FCR is also common among
other cancer survivors, with a review showing 42–70 %
report levels of FCR warranting clinical assessment
(Simard & Savard 2009; Thewes et al. 2012).
There is evidence of a significant negative correlation
between FCR and psychological well-being and health-
related quality of life (Koch et al. 2013; Sarkar et al.
2014). Even years after the initial diagnosis, FCR may re-
duce health-related quality of life and induce psycho-
social morbidity (Koch et al. 2013); however, prospectivestudies are lacking. Further research is required to more
fully understand the relationship between FCR and other
factors, such as anxiety, distress, quality of life, coping,
as well as unmet needs, satisfaction with clinical care,
and health behaviours.
Despite a large proportion of high risk melanoma sur-
vivors reporting persistent fear and uncertainty about
the possibility of new disease, disease recurrence or me-
tastases, few appear to receive professional psychological
support for melanoma-related concerns (McLoone et al.
2012). Qualitative research (Lee-Jones et al. 1997) sug-
gests that people with melanoma tend to feel they do
not belong with other cancer patients in support
groups, and that their fears and concerns may not be
understood by family and friends because of their
seemingly healthy outward appearance and ‘straight
forward’ treatment.
Therefore, management of FCR requires educational
and psychotherapeutic approaches that address emotional,
social, behavioural and cognitive responses to cancer. Re-
search has shown that allowing cancer patients to discuss
their fears may help reduce threats to their emotional
well-being (Lee-Jones et al. 1997). Several interventions
have been developed in the past to facilitate behaviour
change, enhance participants’ coping and adjustment to
melanoma, and improve patient satisfaction with clinical
care (McLoone et al. 2013a). However, no studies have de-
veloped and evaluated psychological support interventions
specifically designed for melanoma survivors at high risk
of new primary disease. To address this gap in psycho-
logical support, our team developed a supportive care pro-
gram designed for melanoma survivors at high risk of
developing new primary disease. The intervention is
multi-faceted and is broadly designed to meet supportive
needs. This study will evaluate both the efficacy and cost-
effectiveness of the newly developed psycho-educational
intervention.
Methods
Study aims and hypotheses
The objective of the study is to improve emotional, so-
cial, behavioural and cognitive adjustment to melanoma
risk amongst melanoma survivors at high risk of devel-
oping new primary disease. The primary aim of the
study is to evaluate, using a randomised controlled trial,
the efficacy of a psycho-educational intervention in
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sured by the Fear of Cancer Recurrence Inventory
(FCRI), compared to usual care. The secondary aims are
to:
 Evaluate the effect of the intervention on anxiety,
depression, unmet supportive care needs, satisfaction
with clinical care, knowledge, quality of life, and
behavioural adjustment to melanoma risk (sun
exposure, sun protection, and skin self-examination);
 Evaluate the cost-effectiveness of the intervention
within the Australian health system; and
 Conduct a process evaluation to try to identify the
‘active ingredients’ of the newly developed
intervention, to inform and facilitate potential
translation and implementation into clinical practice.
We hypothesise that compared with those who receive
usual care (controls), those who receive the newly devel-
oped, tailored psycho-educational intervention will:
a. Report a lower severity sub-scale score on the Fear of
Cancer Recurrence Inventory (Simard & Savard 2009);
b. Have greater understanding of melanoma risk, greater
satisfaction with clinical care, lower depression,
anxiety and stress, healthier behavioural adjustment to
melanoma risk, fewer unmet supportive care needs,
and better health-related quality of life.
Additionally we hypothesise that the intervention will
be cost-effective from a health system perspective.
Design
The Melanoma Care Study is a two-arm randomised
controlled trial in which an efficacy evaluation, an eco-
nomic evaluation, and a process evaluation will be car-
ried out. The Template for Intervention Description and
Replication (TIDieR) checklist and guide, (Hoffmann
et al. 2014) which builds on the CONSORT/SPIRIT
statements, (Campbell et al. 2004) will be used to report
the efficacy and cost-effectiveness of the intervention.
The trial is registered with the Australian and New
Zealand Clinical Trials Registry (Registration Number:
ACTRN12613000304730). Ethics approval has been ob-
tained from all relevant Ethics Committees, including
the Sydney Local Health District (RPAH zone) Ethics
Review Committee, the Department of Health and Ageing
Human Research Ethics Committee, the University of
Sydney ethics committee and the Australian Institute of
Health and Welfare Ethics Committee.
Participants
Participants will be eligible for the study if they meet all
of the following criteria: Previously diagnosed with melanoma stage 0, I or II;
 At high risk of developing new primary melanoma
(attending a high risk clinic);
 Able to give informed consent for the study;
 Possess sufficient English language skills to read the
booklet and complete the study questionnaires
without an aide; and
 Aged 18 years or older.
Individuals will not be eligible to take part if they meet
any one of the following criteria:
 Current stage III or IV (metastatic) melanoma, as
research suggests that these patients may have
different psychosocial needs to stage 0/I/II patients
(where the melanoma has been confined to a
primary tumour only);
 At high risk of melanoma but have never had the
disease (e.g. people without melanoma who carry a
high penetrance genetic mutation);
 Have a known past or current diagnosis of severe
major depression, active psychotic illness, or other
serious psychiatric condition or cognitive deficit
(e.g. dementia).
There is no intention to ‘screen’ individuals for FCR
prior to study enrolment. This decision is based on pre-
vious evidence accumulated by our team over the past
10 years, showing that people at high risk of melanoma
report a range of difficulties across various domains in
addition to FCR, including but not limited to, unmet
health information needs, practical issues regarding their
melanoma care, difficulties communicating with their
healthcare team, and challenges in accessing timely and
appropriate psychological support. These difficulties
are considered important to address in the context of
a psycho-educational intervention, irrespective of self-
reported FCR scores and thus, screening is regarded as
unnecessary in this trial. In addition, the ability of the 9-
item FCRI severity subscale to screen for clinical need,
and the appropriate cut-points to use, are yet to be
demonstrated.
Recruitment procedures
Individuals who meet the eligibility criteria will be re-
cruited from melanoma high risk clinics (HRC) across
New South Wales, Australia. These clinics provide a
specialised clinical management service for people at
very high risk of developing further primary melanoma
(Moloney et al. 2014). This includes patients ≥18 years of
age who belong to one or more of the following groups:
 Personal history of ≥1 invasive melanoma and
dysplastic nevus syndrome; or
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with at least one occurring in the 10 years prior to
study recruitment; or
 Personal history of ≥1 invasive melanoma and a
family history of at least three first- or second-degree
relatives with a confirmed history of melanoma; or
 Confirmed carrier of a CDKN2A or CDK4 gene
mutation (the highest penetrance susceptibility gene
mutations for melanoma). No history of invasive
melanoma is required for this group.
The first HRC was established in 2006 at the Sydney
Melanoma Diagnostic Centre at the Royal Prince Alfred
Hospital in metropolitan Sydney. In 2012, the service
expanded to include clinics at the Melanoma Institute
Australia in metropolitan Sydney and the Newcastle Skin
Check Clinic in a regional, coastal area; all three of these
clinics were sources of recruitment for this study. In late
2014, another HRC opened at Westmead Hospital in
metropolitan Sydney. Participants attend these clinics at
least 6-monthly for skin monitoring via a variety of clinical
imaging techniques, including dermoscopy, digital dermo-
scopy and total body photography. Individuals are man-
aged according to the assessment of any lesions detected
(Moloney et al. 2014). Education in skin self-examination
techniques is also provided where appropriate and a record
of skin self-examination is maintained by the individual.
The study invitation package comprising invitation let-
ter, participant information sheet, consent forms, partici-
pation card, and reply paid envelope will be sent as a
bulk mail out to all eligible HRC patients. The letter of
invitation will be signed by each patient’s treating clin-
ician. Participants will be able to opt into the study by
returning the signed consent form and participationFig. 1 Schedule for study questionnaires and telephone-based sessions witcard, or to decline study participation by returning the
non-participation card. Participants who do not return
their consent form or participation card within two
weeks will receive reminder telephone calls. If the par-
ticipant does not return their consent form after these
telephone calls, no further contact will be made. Partici-
pants who opt-in by returning their signed consent form
will be contacted by the study coordinator who will pro-
vide details and timing of the study materials they will
receive, which will be timed according to their next
HRC appointment date (see Fig. 1).
Randomisation
Randomisation will be performed ensuring allocation con-
cealment using the telephone randomisation service at the
National Health and Medical Research Council of Australia
(NHMRC) Clinical Trials Centre, The University of Sydney.
Recruited participants will be assigned an ID code and ran-
domised using minimisation, stratified by HRC site.
To minimise potential contamination, no components
of the intervention will be made available to patients
other than those in the intervention group until after all
data have been collected and the trial is completed.
Some of the HRC clinicians have been involved in devel-
oping and reviewing intervention components, but they
will not be provided with a personal copy and will be
asked not to initiate conversation specifically about the
intervention with their patients. For ethical reasons, we
cannot preclude clinician communication with ‘control’
participants about topics covered by the intervention.
Indeed this may happen regardless of the trial due to
education from other sources; however, time constraints
in the clinic setting are highly likely to minimise con-
tamination among controls.h a psychologist
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The intervention is comprised of two components: a
newly-developed psycho-educational booklet, and three
individual, telephone-based sessions facilitated by a
psychologist.
The psycho-educational booklet entitled, ‘Melanoma:
Questions and Answers’ is a 76-page, full-colour, evidence-
based psycho-educational booklet. It features comprehen-
sive information on a range of topics identified from our
previous research (McLoone et al. 2012) as important to
people with melanoma. The booklet was developed by a
multidisciplinary team with expertise in clinical psych-
ology, psychological aspects of melanoma, dermatology,
melanoma treatment and risk management, genetic
epidemiology, public health, genetic counselling, pa-
tient education, and health economics. The booklet
has seven modules and each module has been de-
signed to stand alone, so that readers can use the dif-
ferent sections as needed. In addition, the booklet has
integrated a series of resources tailored to people with
melanoma such as:
 Graphics and diagrams to communicate risk
information;
 Photographs to illustrate complex health behaviours
such as skin self-examination;
 Verbatim quotes from Australian melanoma patients
of various ages and backgrounds;
 A Question Prompt Sheet, which is a structured list
of questions that patients are encouraged to ask
their doctor if they wish;
 Care planning pages designed to provide patients
with space to record various aspects of melanoma
management, including: diagnosis, treatments,
prognosis, skin biopsies, sentinel or lymph node
biopsies, moles being monitored for change, and
recommended follow-up care such as skin self-
examinations and clinical skin examinations; and
 Up-to-date lists of reputable services and websites.
The booklet was reviewed and revised using an iterative
process in partnership with two advisory panels involving
consumers and health professionals. Representatives from
key professional bodies such as the Australian Psycho-
logical Society, NSW Health, the Psycho-oncology Co-
operative Research Group, and the Melanoma Institute
Australia contributed to this process. The booklet was
developed in accordance with the latest evidence, core
principles of clinical psychology practice, and the Transac-
tional Model of Stress and Coping (Lazarus & Folkman
1984; Folkman 1997). Development was also heavily
guided by the NHMRC guidelines on ‘How to present
the evidence for consumers’ (National Health and Medical
Research Council (NHMRC) 1999), as well as relevantNHMRC clinical practice guidelines (i.e. the ‘Clinical
practice guidelines for the management of melanoma in
Australia and New Zealand’(Australian Cancer Network
Guidelines Revision Working Party 2008), and the ‘Clin-
ical practice guidelines for the psychosocial care of adults
with cancer’) (Centre & Initiative 2003). In addition, the
readability level of all materials was adjusted to 8th grade,
and pictorial representations of disease risk estimates were
developed, as recommended by health communication
experts (Elwyn et al. 2006).
In addition to the psycho-educational booklet, partici-
pants in the intervention group will receive three individ-
ual, telephone-based sessions facilitated by a psychologist.
The three telephone sessions will occur at specific
time points, timed according to participants’ HRC
appointments:
 Session 1 will take place approximately one week
before each participant’s next full dermatological
appointment at the HRC.
 Session 2 will occur approximately one week after
the HRC appointment.
 Session 3 will occur approximately three weeks after
the HRC appointment (i.e. two weeks after Session 2).
As with the booklet, the telephone-based sessions
have been developed in accordance with the latest
evidence in melanoma and psycho-oncology research,
(McLoone et al. 2013a) as well as core principles of
brief psychodynamically-oriented psychotherapy (Abbass
et al. 2009; Blagys & Hilsenroth 2002; Shedler 2010).
The overarching framework of the intervention is to
provide empathic, active listening at a deep level so
as to try to understand the participant and his or her
experiences, and to assist the participant in develop-
ing more effective emotional and behavioural coping
strategies (De Jong & Berg 2002). The telephone
intervention features seven key elements: 1. a focus
on affect and the expression of patients’ emotions; 2. an
exploration of patients’ attempts to avoid topics or en-
gage in activities that may hinder understanding; 3. the
identification of patterns in patients’ actions, thoughts,
feelings, experiences, and relationships; 4. space to ex-
plore past experiences as well as future possibilities; 5. a
focus on patients’ interpersonal experiences; 6. an em-
phasis on the therapeutic relationship; and 7. an explor-
ation of patients’ needs, goals and wishes. Whilst this
basic framework for the sessions will be outlined by the
psychologist, the nature, scope and content of the ses-
sions will be directed by the patient according to his or
her unique and specific experiences, difficulties, needs,
and wishes. The intervention is also designed to assist
the participant in developing the skills and accessing the
resources required to address identified difficulties,
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fear of melanoma recurrence, based on previous research
(Armes et al. 2009; Hodgkinson et al. 2007a; Sanson-
Fisher et al. 2000) and our clinical experience it is
expected that this will frequently arise as a difficulty ex-
perienced by patients. Hence, specific strategies in ad-
dressing FCR are included in the intervention (Butow
et al. 2013), to be utilised as indicated. A comprehensive
manual has been developed by the psychology team to
provide detailed information and protocols relating to all
clinical aspects of the trial.
The telephone sessions are designed to provide patient-
specific assistance (see Table 1). Session 1 (up to 90 min)
features an assessment, including a discussion of each
participant’s background (family, work, friendships, …),
experience of melanoma and clinical care, other health
issues, information and support needs, and their goals
and wishes for the intervention. Subsequent sessions
(up to 50 min each) will focus on exploring each partic-
ipant’s needs and concerns, utilising appropriate psy-
chological techniques and the booklet, ‘Melanoma:
Questions and Answers’. Session 2 will also include ex-
ploration of the participants’ experience of Session 1,
his or her recent HRC appointment and its outcomes,
the clinical care received, and related informationTable 1 Outline of the telephone sessions
Content
Introduction and
scheduling of Session 1
• Therapist introduces herself to the participan
• Check that both booklets have been receive
• Reiterate the aims of the intervention.
• Answer any questions the participant may h
• Explain confidentiality.
• Schedule and set up Session 1.
Session 1: Assessment • Initial assessment of participants’ needs
• Orient the participant to the different section
and Answers, and the different ways in which
• Assist the participant in identifying his or he
• Discuss any concerns the participant may ha
Session 2: HRC
Appointment Follow-up
• Follow-up regarding HRC appointment.
• Review of previous session and any difficulti
• Address participant’s unmet support and info
where relevant.
• Provide information and referral for managin
Session 3: Final session • Follow-up and update since last session.
• Review of previous session and any difficulti
• Discuss the degree to which unmet needs h
• Discuss new strategies to address possible fu
• Orient the participant to relevant services an
future concerns.
• Facilitate referral for psychological interventiand support needs. Session 3 will entail a summary
of issues discussed during the previous two sessions,
and the participant’s experience of working with a
psychologist. Appropriate referrals will also be given
for further information and support, as needed. The
telephone sessions will be recorded with participants’
permission.
Psychologists and intervention training
Psychologists recruited to the study to deliver the
telephone-based sessions will be required to be registered
psychologists, with at least five years clinical experience in
a health-related setting, and to demonstrate a high level of
empathic understanding and communication in a role-
play evaluation with a simulated patient. Once recruited
to the trial (and prior to intervention delivery), the psy-
chologists will undertake a tailored training program fea-
turing five core learning components:
(1)Education in issues relating to melanoma and
melanoma risk management.t over
d.
ave ab
s of t
he o
r unm
ve abo
es disc
rmati
g unm
es disc
ave be
ture c
d reso
on, if inPsychologists will be trained in physical, emotional,
social, behavioural, cognitive and practical issues
commonly experienced by people affected by
melanoma by a senior member of the research teamApproximate duration
the telephone. 15 min
out the trial.
90 min
he booklet, Melanoma: Questions
r she can use the booklet.
et information and support needs
ut their upcoming HRC appointment.
50 min
ussed.
on needs, utilising the booklet
et needs, when appropriate.
50 min
ussed.
en addressed.
oncerns.
urces in the booklet for possible
dicated.
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in the care of people with melanoma (NK).
Psychologists will also be supported in delivering the
intervention through intensive training with the
manual by an experienced psycho-oncology
researcher and psychologist.
(2)Observation of routine clinical practice at the HRCs.
To facilitate an in-depth understanding of the nature
and function of the HRCs and the clinical
interactions that occur between patients and
their healthcare team, psychologists will under-
take a series of observations at different times
and at different HRCs.
(3)Training in the delivery of telephone-based
psycho-educational interventions.
The psychologists will undergo a training workshop
designed to facilitate communication skills in the
delivery of telephone-based psychological interventions
for cancer patients.(Hodgkinson 2008; Shaw et al.
2013) The psychologists will also undertake a role-play
with a professional actor from the Pam McClean
Cancer Centre (www. http://pammcleancentre.org/)
to help them practice and strengthen their telephone-
based skills. The scenario for this role play has been
written by two senior psychologists in the team.
(4)Clinical workshops.
A number of clinical workshops will be made
available to the psychologists throughout the trial, to
support their ongoing professional development.
(5)Weekly supervision.
Throughout the entire intervention, psychologists
will attend weekly clinical supervision with a senior
psychologist (NK).
Study procedures
Figure 2 illustrates the procedures of the trial. Once con-
sented, participants will be asked to complete a paper-
or web-based baseline questionnaire, depending on their
preference, approximately 6 weeks before their next 6-
monthly dermatological consultation at the HRC. Once
the completed baseline questionnaire is received, the
participant will be randomised into either the interven-
tion or control group. After randomisation, 3–4 weeks
before their HRC appointment, the research team will
send the participant the appropriate study package, in-
cluding a letter describing which group they have been
randomly allocated to, and the next steps in the study.
In the following week, participants in the intervention
arm will be contacted by telephone by the assigned
psychologist to arrange a suitable time for the first inter-
vention session, and all three sessions will be facilitated
by the same psychologist.
All participants will receive four study questionnaires
in total; one at baseline (T0, about 6 weeks prior to theirnext full dermatological consultation at the HRC), one
4 weeks after their HRC consultation (which occurs
soon after their third telephone session for those in the
intervention group) (T1), and again 1 week after their
subsequent full HRC consultation 6 months later (T2),
and 12 months later (T3) (see Fig. 2). The 12 month as-
sessment (T3) will assess longer-term effects of the
intervention, but is only planned if effectiveness of the
intervention is demonstrated at 6 months. Participants
who do not complete and return the study question-
naires in the specified time period will be contacted by
the research team via telephone or email, as a reminder
about the study.
Outcome measures
The primary outcome will be based on the third ques-
tionnaire at 6 months (T2).
Effect evaluation
Table 2 provides an overview of the measures of efficacy,
economic evaluation, and timing of measurement.
Primary outcome measure
The primary outcome in this study is the level of self-re-
ported fear of new or recurrent melanoma assessed using
the severity sub-scale of a modified (i.e. melanoma-spe-
cific) version the 42-item Fear of Cancer Recurrence In-
ventory (FCRI). (Simard & Savard 2009) A higher FCRI
score is indicative of greater FCR. The other six sub-scales
of the FCRI (triggers, psychological distress, functional im-
pairment, reassurance, insight, and coping strategies) will
also be analysed as outcomes. Previous research has dem-
onstrated high internal consistency (α = 0.75–0.91) and
reasonable temporal stability (r = 0.58–0.83) of the sub-
scales of the FCRI, as well as good criterion validity when
compared with other self-report scales assessing fear of
cancer recurrence (r = 0.68 to 0.77) or related constructs
(Simard & Savard 2009).
Secondary outcome measures
General depression, anxiety and stress: measured using
the short version of the Depression Anxiety and Stress
Scales (DASS-21) (Lovibond & Lovibond 1995). The
DASS-21 is a set of three 7-item self-report scales de-
signed to measure the emotional states of depression,
anxiety and stress. The total score of each subscale of
the DASS-21 is classified from “normal” to “extremely
severe”.
Health-related quality of life (HRQoL): HRQoL will be
assessed using two measures. The Assessment of Quality
of Life—8 Dimensions (AQoL-8D) is a 35-item health-
related QoL preference-based measure, specifically de-
veloped for mental health, with norms for the Australian
population by age and sex. The AQOL-8D produces
Fig. 2 Flow diagram
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Table 2 Measures and timing of assessment in the Melanoma care study
Variables Measures Baseline (T0) T1* T2Φ T3‡
Fear of new or recurrent melanoma Fear of Cancer Recurrence Inventory ✓ ✓ ✓ ✓
Depression, anxiety, stress and depression Depression Anxiety and Stress Scales (DASS-21) ✓ ✓ ✓ ✓
Health related quality of life AQOL-8D and FACT-M ✓ ✓ ✓
Knowledge A 9 item scale specifically developed for this study ✓ ✓ ✓ ✓
Healthy behavioural adjustment to melanoma risk The Sun Protection Habits Scale (SPHS) and adapted
items for sun protection and skin self examination
✓ ✓ ✓
Satisfaction with clinical care Consultation Satisfaction Questionnaire (CSQ) ✓ ✓ ✓
Unmet information and support needs Modified Cancer Survivors’ Unmet Needs (CaSUN) ✓ ✓ ✓
Resource use and cost outcomes Items developed for this study (resource use) and
Medicare data (PBS and MBS)
✓ ✓ ✓
Health literacy ✓
Medical record From the melanoma clinics’ databases ✓ ✓ ✓
Process evaluation Developed for use in this study. ✓ ✓
Demographic and other risk factors Age, gender, marital status, number of children,
education, income, occupation
✓
*T1: 6 weeks after randomisation, ΦT2: 7 months after randomisation, ‡T3: 13 months after randomisation
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used in economic evaluations (Richardson et al. 2009;
Richardson & Iezzi 2010). The Functional Assessment of
Cancer Therapy (FACT-M) (Cormier et al. 2005) (melan-
oma) contains the 27 core items of the FACT–G (general),
plus an additional 24 melanoma-specific items encom-
passing three domains: physical well-being (20 items),
emotional well-being (3 items), and social well-being (1
item). The FACT-M yields both a total QoL score as well
as domain scores. An algorithm is available to transform
FACT-M scores to utilities for QALY estimation, thereby
facilitating a comparison of health economic outcomes.
Behavioural adjustment to melanoma risk: Three
melanoma-related behaviours will be assessed: sun ex-
posure, sun protection, and skin self-examination. Three
items from the consensus-based set of core survey items
developed by Glanz et al. will be used to assess sun ex-
posure (Glanz et al. 2008). One item will assess instances
of sunburn in the past 12 months. The Sun Protection
Habits Scale (Glanz et al. 2002) will be adapted to assess
the use of seven sun protection behaviours (e.g. sun-
screen use). Engagement in skin self-examination will be
assessed with three items adapted from Manne et al.
(Manne & Lessin 2006).
Satisfaction with clinical care: will be measured using
the Consultation Satisfaction Questionnaire (CSQ) (Baker
1990). The CSQ is comprised of 18 items assessing: general
satisfaction (3 items); professional care (7 items); depth of
relationship (5 items); and perceived time (3 items).
Unmet information and support needs: will be assessed
using an adapted version of the Cancer Survivors’ Unmet
Needs (CaSUN) questionnaire, which includes needs re-
lated to information, medical, emotional, quality of life, life
perspective (Hodgkinson et al. 2007b; Hodgkinson et al.2007c). The CaSUN includes 35 unmet need items, 6 posi-
tive change items and an open-ended question.
Knowledge: A purposely-designed set of items was de-
veloped to assess knowledge of specific issues covered in
the booklet ‘Melanoma: Questions and Answers’.
Covariates
Information on demographic factors including age, sex,
marital status, education, number of children, health liter-
acy and total family income will be collected. In addition,
clinical information such as their doctor’s name, presence
of dysplastic nevus syndrome, presence of high penetrance
genetic mutation, family history of melanoma, dates of
personal melanoma diagnoses, melanoma American Joint
Committee on Cancer (AJCC) stage, Breslow thickness,
site of the melanoma(s), and other major illnesses will be
extracted from the clinic records.
Sample size
Sample size calculation has been based on 80 % power
and a two-sided α = 0.05 test. Because there is no exist-
ing literature or clinical opinion to provide an estimate
of the minimal clinically important difference, a standar-
dised mean difference (Cohen’s d) of 0.5 was employed,
which is a moderate effect size and has been found to be
applicable to a wide variety of patient-reported outcomes
(Norman et al. 2003). Based on these values, the sample
size required is 64 per group. When taking into account
the expected attrition rate of 20 %, the sample size re-
quired is 77 per group (154 total).
Economic evaluation
A trial-based economic evaluation will be conducted
from a health system perspective. The following items
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and valued:
 Cost of the production of the psycho-educational
booklet;
 Psychologist costs;
 Number of telephone sessions and duration;
 Access to external psychological services;
 Hospital admissions; and
 Prescribed medications.
Health service use and costs of the intervention will be
estimated using three methods: 1) the Australian Medi-
care Benefits Schedule (MBS) and Pharmaceutical Benefits
Scheme (PBS) databases (individual informed consent was
obtained to access to these individual-level data); 2) self-
report regarding use of healthcare resources not covered
by the MBS and PBS databases; and 3) trial records, in-
cluding research team and psychologist records related to
intervention delivery.
In the economic evaluation, total and mean costs for
the intervention and control group will be reported in a
disaggregated format. Total and mean severity outcomes
(FCRI Severity subscale score and AQOL-8D utility
(quality of life score)) will be reported for the interven-
tion and control groups. The difference in mean scores
between the two groups will be assessed with appropri-
ate statistical tests. Incremental cost-effectiveness ratios
will be calculated in terms of: a) the incremental cost
per participant achieving a significant decrease in mean
FCRI Severity score (0.5 of the SD on the FCRI Severity
subscale which is considered to be a meaningful change)
(Norman et al. 2003); and b) the incremental cost per
quality-adjusted life year (QALY) gained in the interven-
tion group compared with the control group. Results will
be plotted on a cost-effectiveness plane. Bootstrapping
will be used to estimate a distribution around costs and
health outcomes and to estimate the confidence intervals
around the incremental cost-effectiveness ratio (Medical
Services Advisory Committee MSAC 2000; Drummond
et al. 2005; Gold et al. 1996). One-way sensitivity ana-
lysis will be conducted around key variables including
the QoL instruments, and a cost-effectiveness accept-
ability curve (CEAC) will be plotted (Medical Services
Advisory Committee MSAC 2000; Drummond et al.
2005; Gold et al. 1996).
Process evaluation
A process evaluation will also be undertaken to: a) assess
intervention fidelity and reach; b) assess participants’ sat-
isfaction with and acceptability of the intervention; and
c) provide data to assist in interpreting the outcomes of
the trial. These process evaluation questions have been
developed by operationalising key elements of processevaluations (as described by Baranowski and Stables,
and Linnan and Steckler (Baranowski & Stables 2000;
Linnan 2002; Saunders et al. 2005)), into structured
items. Data will be collected using questionnaires com-
pleted by participants, listening to a selection of the
recorded telephone sessions checklists and notes kept
throughout the trial by psychologists, and research
notes. Descriptive statistics, Chi-square and t-tests will
be used to analyse data from the process evaluation.
Statistical analyses
The primary analysis will be by intention to treat. For
both primary and secondary endpoints, linear mixed
models will be used to analyse the data to account for
the repeated measures (and therefore non-independent)
data collected from patients. These models will enable
the comparison of potential changes in patient responses
over time, whether the treatment and control arms differ
from each other, and whether any changes over time differ
between the treatment arms (that is, whether there is a
time-by-treatment interaction). Several socio-demographic
variables (e.g. age, sex, income, education level, marital
status) will be statistically controlled for by appropriate
inclusion as covariates in the mixed models.
Discussion
Significance
To our knowledge, the Melanoma Care Study will be the
first randomised clinical trial to test an intervention spe-
cifically aimed at improving the psychological health and
well-being of melanoma survivors at high risk of devel-
oping new primary disease. The study will investigate
how the newly-developed intervention influences psy-
chosocial outcomes reported by people affected by mel-
anoma, with a focus on FCR, psychological health and
well-being, melanoma-related actions and behaviours,
unmet information and support needs, satisfaction with
clinical care, risk-related knowledge and understanding,
and cost-effectiveness. This trial aims to strengthen the
literature and to bridge the gap between existing re-
search evidence demonstrating a critical need for
psycho-educational support for melanoma patients, and
clinical practice.
Strengths
The Melanoma Care Study has several strengths.
First, the newly developed intervention is based on
extensive previous research by our group and others
(McLoone et al. 2013a; McLoone et al. 2012; McLoone
et al. 2013b) identifying a range of psychological needs
and experiences reported by high risk melanoma survi-
vors. These experiences include: high levels of fear re-
garding melanoma recurrence or the development of
new primaries, low confidence and skill in skin self-
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psychological care, limited use of effective coping strat-
egies, difficulties understanding and interpreting com-
plex medical information, and challenges associated with
satisfaction with clinical care. A wide range of evidence-
based features have been integrated into the intervention
to address these common difficulties. In addition, the
timing of the support sessions has been based around
patients’ full dermatological appointments at the HRC,
as this is a time of peak anxiety for patients. For ex-
ample, a recent study by Morton et al. on melanoma pa-
tients’ experiences of follow-up found that anxiety was a
major concern starting from one week prior to clinical
visit (Morton et al. 2013). Third, the systematic recruit-
ment of large numbers of high risk individuals through
the HRCs provides a unique opportunity to address the
research questions with sufficient power and in a timely
manner. Fourth, the investigation of cost-effectiveness
provides evidence to support policy-makers regarding
adoption and reimbursement of the intervention, as pre-
vious research has found economic evaluations are often
overlooked in intervention research (Badr & Krebs
2013). Fifth, the conduct of a process evaluation along-
side the trial adds value and can facilitate translation and
implementation of study results, if positive, into future
clinical practice. Research has demonstrated that process
evaluation can play an important role in the evaluation
of complex interventions (Campbell et al. 2000) and the
process data can be useful when trying to explain why
an intervention may work or fail to work (Elford et al.
2001; Stapleton et al. 2002).
Limitations
Despite these strengths, the study presents several chal-
lenges. The first challenge is whether the scale used to
measure the primary outcome (FCRI) will have the sensi-
tivity required to detect any changes experienced by this
particular cohort. To overcome this challenge, the FCRI
has been subjected to confirmatory factor analysis and
item response theory analysis in order to examine its
measurement properties in melanoma survivors (submit-
ted for publication). Another challenge of the study is that
participants were not screened for any psychological vari-
able (e.g. FCR, anxiety or depression) before trial enrol-
ment. Indeed, patients with no information or support
needs may perceive a lack of usefulness of the intervention
which may influence the number of participants who
withdraw from the study. However, the intervention was
broadly designed to meet the supportive care needs of
melanoma survivors at high risk, and FCR was one part of
the overall suite of issues that we wanted to address.
Furthermore, the psychologists have been trained to
work with participants to identify needs and tailor the
intervention accordingly.Future implementation
In 2008, the NHMRC Clinical Practice Guidelines for
the Management of Melanoma recommended that psy-
cho-education be made available to all patients with
melanoma (Australian Cancer Network Guidelines
Revision Working Party 2008). This signals a high
potential for rapid translation of effective interventions
into the clinic, if evidence for the efficacy of this inter-
vention in improving psychological health and well-being
is found, and it is also cost-effective.
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